Study wrapper · #858
Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: Results from the PERCEPTIONS survey.
Gibble TH, Makin H, Gerber C, et al. Obesity pillars. 2026.
DOI: 10.1016/j.obpill.2026.100288PubMed: 42436850
Editor's note
Baseline data from the observational PERCEPTIONS survey capturing why 518 adults with obesity started tirzepatide and how they experienced it early on, with cost and insurance coverage the dominant barriers. This is descriptive, patient-reported, and cross-sectional, so it speaks to real-world motivations and access rather than efficacy. Note the industry sponsorship context typical of SURMOUNT-adjacent work; still, it is useful signal on the lived experience and market friction around tirzepatide.
Plain-language abstract
A survey of 518 people starting tirzepatide for weight management found most were motivated by overall health and self-confidence, found the injector easy to use, and cited cost and insurance as the main barriers.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Weak / none
Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.
Tissue & celln=——2026
Mixed
Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
Obesity pillarsn=——2026